A	C177536	GDC Property Terminology	C164791	Document Version Identifier		revision	
C	C177536	GDC Property Terminology	C17001	Ploidy	The number of chromosome sets per cell.	ploidy	
A	C177536	GDC Property Terminology	C185248	Read Group Pairs on Different Chromosomes Data	Sequencing read quality control data detailing the number of pairs where one read is on one chromosome and the other read is on a different chromosome.	pairs_on_diff_chr	pairs on diff chr
A	C177536	GDC Property Terminology	C185249	Base Mismatch Proportion Data	Sequencing read quality control data detailing the relative proportion of base mismatches that occurred during a nucleotide sequencing run.	proportion_base_mismatch	proportion base mismatch
A	C177536	GDC Property Terminology	C185250	Proportion of Duplicated Reads Data	Sequencing read quality control data detailing the relative proportion of duplicate reads that occurred during a nucleotide sequencing run.	proportion_reads_duplicated	proportion reads duplicated
A	C177536	GDC Property Terminology	C185251	Proportion of Mapped Reads Data	Sequencing read quality control data detailing the relative proportion of mapped reads detected during a nucleotide sequencing run.	proportion_reads_mapped	proportion reads mapped
A	C177536	GDC Property Terminology	C185252	Clinical Center Type Acronym	The acronym for the type of center that is running a clinical program, trial or study	center_type	center type
A	C177536	GDC Property Terminology	C185253	ICD-10 Code	The alphanumeric code assigned to an entity in the tenth version of the International Classification of Disease (ICD-10).	icd_10_code	icd 10 code
A	C177536	GDC Property Terminology	C185254	Exposure Duration Years	The period of time from start to finish of an exposure expressed in years.	exposure_duration_years	exposure duration years
A	C177536	GDC Property Terminology	C185255	Exon of Interest Number	The number indicating the position of an exon that is either involved in a molecular variation or of interest in an experiment or study.	exon	
A	C177536	GDC Property Terminology	C185256	Intron of Interest Number	The number indicating the position of an intron that is either involved in a molecular variation or of interest in an experiment or study.	intron	
A	C177536	GDC Property Terminology	C185257	Second Exon of Interest Number	The number indicating the position of a second exon that is either involved in a molecular variation or of interest in an experiment or study.	second_exon	second exon
A	C177536	GDC Property Terminology	C185258	Total Area of Mitotic Index Ratio Analysis	The total area examined to determine the mitotic ratio index.	mitotic_total_area	mitotic total area
A	C177536	GDC Property Terminology	C185259	Biospecimen Portion Number	The number specifying the location of a portion that was isolated from a biospecimen for further investigation relative to other isolates from the same source.	portion_number	portion number
A	C177536	GDC Property Terminology	C185260	Percent Tumor Invasion	A quantitative measurement of the percent of tumor cells that are found in tumor adjacent tissue.	percent_tumor_invasion	percent tumor invasion
A	C177536	GDC Property Terminology	C185261	Extraocular Nodule Size	The dimensions of the a nodule found near but outside the eye.	size_extraocular_nodule	size extraocular nodule
A	C177536	GDC Property Terminology	C185262	Biospecimen Portion Creation Date Time	The date and time that a portion of a biospecimen was isolated from the source specimen for further investigation.	creation_datetime	creation datetime
A	C177536	GDC Property Terminology	C185264	Read Group Adapter Content Quality Control Indicator	An indication for whether a nucleotide sequencing read group file has associated adapter content quality control data and whether the outcome was pass, fail or warn.	adapter_content	adapter content
A	C177536	GDC Property Terminology	C185265	Read Group Basic Statistics Quality Control Indicator	An indication for whether a nucleotide sequencing read group file has associated basic statistic quality control data and whether the outcome was pass, fail or warn.	basic_statistics	basic statistics
A	C177536	GDC Property Terminology	C185266	Read Group Kmer Content Quality Control Indicator	An indication for whether a nucleotide sequencing read group file has associated Kmer content quality control data and whether the outcome was pass, fail or warn.	kmer_content	kmer content
A	C177536	GDC Property Terminology	C185267	Read Group Overrepresented Sequences Quality Control Indicator	An indication for whether a nucleotide sequencing read group file has associated overrepresented sequences quality control data and whether the outcome was pass, fail or warn.	overrepresented_sequences	overrepresented sequences
A	C177536	GDC Property Terminology	C185268	Read Group Per Base N Content Quality Control Indicator	An indication for whether a nucleotide sequencing read group file has associated per base N content quality control data and whether the outcome was pass, fail or warn.	per_base_n_content	per base n content
A	C177536	GDC Property Terminology	C185269	Read Group Per Base Sequence Content Quality Control Indicator	An indication for whether a nucleotide sequencing read group file has associated per base sequence content quality control data and whether the outcome was pass, fail or warn.	per_base_sequence_content	per base sequence content
A	C177536	GDC Property Terminology	C185270	Read Group Per Base Sequence Quality Indicator	An indication for whether a nucleotide sequencing read group file has associated per base sequence quality data and whether the outcome was pass, fail or warn.	per_base_sequence_quality	per base sequence quality
A	C177536	GDC Property Terminology	C185271	Read Group Per Sequence G/C Content Quality Control Indicator	An indication for whether a nucleotide sequencing read group file has associated per sequence guanine/cytosine (G/C) content quality control data and whether the outcome was pass, fail or warn.	per_sequence_gc_content	per sequence gc content
A	C177536	GDC Property Terminology	C185272	Read Group Per Sequence Quality Score Indicator	An indication for whether a nucleotide sequencing read group file has associated per sequence quality scoring data and whether the outcome was pass, fail or warn.	per_sequence_quality_score	per sequence quality score
A	C177536	GDC Property Terminology	C185273	Read Group Per Tile Sequence Quality Indicator	An indication for whether a nucleotide sequencing read group file has associated per tile sequence quality data and whether the outcome was pass, fail or warn.	per_tile_sequence_quality	per tile sequence quality
A	C177536	GDC Property Terminology	C185274	Read Group Sequence Duplication Levels Quality Control Indicator	An indication for whether a nucleotide sequencing read group file has associated sequence duplication levels quality control data and whether the outcome was pass, fail or warn.	sequence_duplication_levels	sequence duplication levels
A	C177536	GDC Property Terminology	C185275	Read Group Sequence Length Distribution Quality Control Indicator	An indication for whether a nucleotide sequencing read group file has associated sequence distribution length quality control data and whether the outcome was pass, fail or warn.	sequence_length_distribution	sequence length distribution
A	C177536	GDC Property Terminology	C185276	Biospecimen Growth Rate	The time it takes for a biospecimen to proliferate in vitro.	growth_rate	growth rate
D	C177537	GDC Value Terminology	C101259	Pegylated Recombinant L-asparaginase Erwinia chrysanthemi	A pegylated, recombinant form of L-asparaginase derived from the bacterium Erwinia chrysanthemi (mPEG-R-Crisantaspase), with potential antineoplastic activity. Upon intravenous administration of pegylated recombinant L-asparaginase Erwinia chrysanthemi, asparaginase hydrolyzes L-asparagine to L-aspartic acid and ammonia, thereby depleting cancer cells of asparagine thus blocking protein synthesis and tumor cell proliferation. Asparagine is critical to protein synthesis in cancer cells, which cannot synthesize this amino acid due to the absence of the enzyme asparagine synthase. Compared to other available Erwinia chrysanthemi derived L-asparaginase agents, the pegylated form is longer acting and less immunogenic.	Pegylated Recombinant L-asparaginase Erwinia chrysanthemi | therapeutic_agents	C1909	therapeutic_agents
D	C177537	GDC Value Terminology	C102749	Heparan Sulfate Glycosaminoglycan Mimetic M402	A low molecular weight heparin derivative and heparan sulfate proteoglycan (HSPG) mimetic with no or minimal anticoagulant activity and potential antineoplastic activities. Upon administration, M402 mimics HSPGs by binding to and inhibiting various heparin-binding growth factors, chemokines, and cytokines such as VEGF, HGF, FGF2, SDF-1a, heparanase and P-selectin all of which are essential for tumor angiogenesis and metastasis to occur. This inhibits heparin binding growth factor-mediated signaling and disrupts tumor-stromal interactions eventually leading to an inhibition of angiogenesis and tumor cell progression. In addition, M402 may enhance the cytotoxic effect of other chemotherapeutic agents.	Heparan Sulfate Glycosaminoglycan Mimetic M402 | therapeutic_agents	C1909	therapeutic_agents
D	C177537	GDC Value Terminology	C102983	PBN Derivative OKN-007	A disulfonyl derivative of phenyl-tert-butyl nitrone (PBN), with potential anti-glioma activity. Although the exact mechanism(s) of action of OKN007 are still largely unknown, this agent appears to inhibit cancer cell proliferation and migration. This agent appears to inhibit the activity of sulfatase 2 (SULF2), a highly specific endoglucosamine-6-sulfatase that is overexpressed in the extracellular matrix of cancer cells and catalyzes the removal of sulfate from the 6-O-sulfate esters of heparin. In addition, OKN007 may induce changes in tumor metabolism and scavenge free radicals.	PBN Derivative OKN-007 | therapeutic_agents	C1909	therapeutic_agents
D	C177537	GDC Value Terminology	C106370	c-Met Inhibitor MSC2156119J	An orally bioavailable inhibitor of the proto-oncogene c-Met (also known as hepatocyte growth factor receptor (HGFR)) with potential antineoplastic activity. c-Met inhibitor MSC2156119J selectively binds to c-Met, which inhibits c-Met phosphorylation and disrupts c-Met-mediated signal transduction pathways. This may induce cell death in tumor cells overexpressing c-Met protein or expressing constitutively activated c-Met protein. c-Met, a receptor tyrosine kinase overexpressed or mutated in many tumor cell types, plays key roles in tumor cell proliferation, survival, invasion, metastasis, and tumor angiogenesis.	c-Met Inhibitor MSC2156119J | therapeutic_agents	C1909	therapeutic_agents
D	C177537	GDC Value Terminology	C111988	FGFR Inhibitor Debio 1347	An orally bioavailable inhibitor of the fibroblast growth factor receptor subtypes 1 (FGFR-1), 2 (FGFR-2) and 3 (FGFR-3), with potential antineoplastic activity. FGFR inhibitor debio 1347 binds to and inhibits FGFR-1, -2, and -3, which result in the inhibition of FGFR-mediated signal transduction pathways. This leads to the inhibition of both tumor cell proliferation and angiogenesis, and causes cell death in FGFR-overexpressing tumor cells. FGFR, a family of receptor tyrosine kinases upregulated in many tumor cell types, is essential for tumor cellular proliferation, differentiation and survival.	FGFR Inhibitor Debio 1347 | therapeutic_agents	C1909	therapeutic_agents
D	C177537	GDC Value Terminology	C111995	Anti-SLITRK6 Monoclonal Antibody-MMAE Conjugate AGS15E	An antibody-drug conjugate (ADC) composed of a monoclonal antibody directed against SLIT and NTRK-like protein 6 (SLITRK6), covalently linked to the cytotoxic agent monomethyl auristatin E (MMAE), an auristatin derivative and a potent inhibitor of microtubule polymerization, with potential antineoplastic activity. Upon intravenous administration, the monoclonal antibody moiety of AGS15E binds to SLITRK6 expressed on tumor cells, which facilitates both AGS15E internalization and the intracellular delivery of MMAE. Upon cleavage, MMAE binds to tubulin and inhibits its polymerization, which results in G2/M phase arrest and tumor cell apoptosis.  SLITRK6, a member of the Slitrk family of leucine-rich repeat (LRR) neuronal transmembrane proteins, is minimally expressed in normal tissue but overexpressed in a variety of cancers, including bladder cancer, some forms of lung cancer, breast cancer and glioblastoma.	Anti-SLITRK6 Monoclonal Antibody-MMAE Conjugate AGS15E | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C112004	p70S6K/Akt Inhibitor M-2698	An orally available inhibitor of the serine/threonine protein kinases ribosomal protein S6 Kinase (p70S6K) and Akt (protein kinase B), with potential antineoplastic activity. Upon administration, p70S6K/Akt inhibitor M-2698 binds to and inhibits the activity of p70S6K and Akt. This prevents the activation of the PI3K/Akt/p70S6K signaling pathway and inhibits tumor cell proliferation in cancer cells that have an overactivated PI3K/Akt/p70S6K signaling pathway. Constitutive activation and dysregulated signaling of the PI3K/Akt/p70S6K pathway are frequently associated with tumorigenesis of many tumor types; targeting multiple kinases in this pathway is more efficacious than targeting a single kinase.	p70S6K/Akt Inhibitor MSC2363318A | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C116850	HDAC Inhibitor REC-2282	An orally available phenylbutyrate-derived histone deacetylase (HDAC) inhibitor, with potential antineoplastic activity. Upon oral administration, REC-2282 inhibits the catalytic activity of HDAC, which results in an accumulation of highly acetylated chromatin histones, the induction of chromatin remodeling and an altered pattern of gene expression. This leads to the inhibition of tumor oncogene transcription, and the selective transcription of tumor suppressor genes, which inhibits tumor cell division and induces tumor cell apoptosis. HDAC, an enzyme upregulated in many tumor types, deacetylates chromatin histone proteins.	HDAC Inhibitor AR-42 | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C120101	Src/tubulin Inhibitor KX2-361	A lipophilic, orally available inhibitor of both Src kinase activity and tubulin polymerization, with potential antineoplastic activity. Upon oral administration,Src/tubulin Inhibitor KX2-361 binds to and inhibits the activity of Src kinase. This inhibits both downstream signaling and the proliferation of Src kinase-expressing tumor cells. KX02 also binds to tubulin heterodimers and inhibits microtubule polymerization, thereby disrupting microtubule formation, mitosis, and further proliferation. Src, a non-receptor tyrosine kinase, is overexpressed in a variety of tumor cell types and plays a key role in tumor cell proliferation, angiogenesis, migration, and metastasis.	Src/tubulin Inhibitor KX02 | therapeutic_agents	C1909	therapeutic_agents
D	C177537	GDC Value Terminology	C124651	GITR Agonist MEDI1873	An agonist of human glucocorticoid-induced tumor necrosis factor receptor (tumor necrosis factor superfamily, member 18; TNFRSF18; GITR), with potential immunomodulating and antineoplastic activities. Upon administration, GITR agonist MEDI1873 binds to GITR found on multiple types of T-cells, thereby inducing both the activation and proliferation of tumor antigen-specific T effector cells. This abrogates the suppression of T effector cells which is induced by inappropriately activated T regulatory cells (Tregs), and activates the immune system to help eradicate tumor cells. GITR, a member of the TNF receptor superfamily, is expressed on the surface of multiple types of immune cells, including regulatory T-cells, effector T-cells, B-cells, dendritic cells (DCs) and natural killer (NK) cells.	GITR Agonist MEDI1873 | therapeutic_agents	C1909	therapeutic_agents
D	C177537	GDC Value Terminology	C128246	XPO1 Inhibitor SL-801	An orally bioavailable inhibitor of the nuclear export protein exportin-1 (XPO1; chromosome region maintenance 1 protein homolog; CRM1), with potential antineoplastic and pro-apoptotic activities. Upon administration, XPO1 inhibitor SL-801 reversibly binds to the cargo binding site of XPO1, and prevents the XPO1-mediated nuclear export of cargo proteins, including tumor suppressor proteins (TSPs), such as p53, FOXO, p21, and p27, and leads to their selective accumulation in the nuclei of tumor cells. As a selective inhibitor of nuclear export (SINE), SL-801 restores the nuclear localization and function of TSPs, which leads to the induction of apoptosis in tumor cells. XPO1, the major export factor that transports proteins and RNA from the nucleus to the cytoplasm, is overexpressed in a variety of cancer cell types while minimally expressed in normal, healthy cells. The dysregulated export of TSPs into the cytoplasm prevents TSP-initiated apoptosis. XPO1 overexpression leads to uncontrolled tumor cell proliferation and is associated with poor prognosis.	XPO1 Inhibitor SL-801 | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C129271	Astrocytoma, IDH-Mutant, Grade 2	IDH-mutant astrocytoma characterized by the presence of well-differentiated fibrillary glial cells diffusely infiltrating the central nervous system.	Diffuse astrocytoma, IDH-mutant | primary_diagnosis	C177621	primary_diagnosis
C	C177537	GDC Value Terminology	C129290	Astrocytoma, IDH-Mutant, Grade 3	IDH-mutant astrocytoma characterized by the presence of increased mitotic activity and anaplastic features.	Anaplastic astrocytoma, IDH-mutant | primary_diagnosis	C177621	primary_diagnosis
C	C177537	GDC Value Terminology	C129319	Oligodendroglioma, Not Otherwise Specified	A central nervous system tumor with morphological features of oligodendroglioma in which there is insufficient information on the IDH genes and 1p/19q codeletion status.	9450/3 | morphology || Oligodendroglioma, NOS | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
C	C177537	GDC Value Terminology	C129327	Anaplastic Pleomorphic Xanthoastrocytoma	A WHO grade 3 pleomorphic xanthoastrocytoma characterized by the presence of five or more mitoses per 10 high-power fields. Necrosis may be present. Patients have shorter survival rates when compared to those with WHO grade 2 pleomorphic xanthoastrocytoma.	Anaplastic pleomorphic xanthroastrocytoma | primary_diagnosis	C177621	primary_diagnosis
D	C177537	GDC Value Terminology	C129968	MAGE-A3 Multipeptide Vaccine GL-0817	A proprietary, peptide cancer vaccine comprised of multiple peptides derived from human melanoma antigen A3 (MAGE-A3; MAGEA3), with potential immunostimulating and antineoplastic activities. Upon administration, MAGE-A3 multipeptide vaccine GL-0817 may stimulate the immune system to mount specific responses from B-cells, and CD4-positive and CD8-positive cells against tumor cells expressing MAGE-A3, resulting in tumor cell lysis. MAGE-A3, a tumor-associated antigen (TAA), is overexpressed by a variety of cancer cell types.	MAGE-A3 Multipeptide Vaccine GL-0817 | therapeutic_agents	C1909	therapeutic_agents
D	C177537	GDC Value Terminology	C140162	Personalized Cancer Vaccine RO7198457	An mRNA-based individualized, therapeutic cancer vaccine targeting an unspecified amount of tumor-associated antigens (TAAs) that are specifically expressed in the patient's cancer, with potential immunostimulatory and antineoplastic activities. Upon administration, the personalized cancer vaccine RO7198457 is taken up and translated by antigen presenting cells (APCs) and the expressed protein is presented via major histocompatibility complex (MHC) molecules on the surface of the APCs. This leads to an induction of both cytotoxic T-lymphocyte (CTL)- and memory T-cell-dependent immune responses against cancer cells expressing the TAA(s).	Personalized Cancer Vaccine RO7198457 | therapeutic_agents	C1909	therapeutic_agents
D	C177537	GDC Value Terminology	C147026	Anti-CD33/CD3 BiTE Antibody AMG 673	A bispecific T-cell engager (BiTE) antibody composed of two single-chain variable fragments (scFv), one directed against the tumor-associated antigen (TAA) CD33 fused to one that is directed against the CD3 antigen found on T-lymphocytes, with potential immunostimulating and antineoplastic activities. Upon administration, anti-CD33/CD3 BiTE antibody AMG 673  binds to both the CD3 antigen on cytotoxic T-lymphocytes (CTLs) and the CD33 antigen found on CD33-expressing tumor cells. This activates and redirects CTLs to CD33-expressing tumor cells, which results in the CTL-mediated cell death of CD33-expressing tumor cells. CD33, a myeloid differentiation antigen, is expressed on normal non-pluripotent hematopoietic stem cells and overexpressed on a variety of cancer cell types, including acute myeloid leukemia (AML). It plays a key role in tumor initiation, proliferation and progression.	Anti-CD33/CD3 BiTE Antibody AMG 673 | therapeutic_agents	C1909	therapeutic_agents
A	C177537	GDC Value Terminology	C152370	Sirtratumab Vedotin	An antibody-drug conjugate (ADC) composed of sirtratumab, a monoclonal antibody directed against SLIT and NTRK-like protein 6 (SLITRK6), covalently linked to the cytotoxic agent monomethyl auristatin E (MMAE), an auristatin derivative and a potent inhibitor of microtubule polymerization, with potential antineoplastic activity. Upon intravenous administration, the monoclonal antibody moiety of sirtratumab vedotin binds to SLITRK6 expressed on tumor cells, which facilitates both the internalization of the ADC and the intracellular delivery of MMAE. Upon cleavage, MMAE binds to tubulin and inhibits its polymerization, which results in G2/M phase arrest and tumor cell apoptosis.  SLITRK6, a member of the Slitrk family of leucine-rich repeat (LRR) neuronal transmembrane proteins, is minimally expressed in normal tissue but overexpressed in a variety of cancers, including bladder cancer, some forms of lung cancer, breast cancer and glioblastoma.	Anti-SLITRK6 Monoclonal Antibody-MMAE Conjugate AGS15E | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C1562	Rhenium Re 186 Etidronate	An synthetic compound containing the organic phosphonate hydroxyethylidene diphosphonate (HEDP) labeled with the radioisotope rhenium Re 186. Re-186 etidronate binds to hydroxyapatite in bone, delivering a cytotoxic dose of beta radiation to primary and metastatic bone tumors. Re-186 is a beta emitter with a short half-life, a radioisotope profile that provides localized antitumor radiocytotoxicity while sparing extramedullary bone marrow tissues.	Rhenium Re-186 Hydroxyethylidene Diphosphonate | therapeutic_agents	C1909	therapeutic_agents
D	C177537	GDC Value Terminology	C159609	Anti-CEACAM6 Antibody BAY1834942	A humanized monoclonal antibody directed against the immune checkpoint regulator carcinoembryonic antigen-related cell adhesion molecule 6 (CEACAM6; CEACAM-6; CD66c), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-CEACAM6 antibody BAY1834942 targets, binds to and blocks the activity of CEACAM6 expressed on various tumor and immune cells, including T-cells. Blocking CEACAM6 signaling abrogates effector T-cell inhibition, activates antigen-specific T-lymphocytes, increases secretion of T-cell cytokines and effector molecules, and enhances cytotoxic T-cell-mediated tumor cell lysis, which results in a reduction in tumor cell proliferation. CEACAM6, an immune checkpoint receptor, is associated with tumor-mediated immune suppression. Elevated CEACAM6 expression is associated with advanced tumor stages and poor prognosis.	Anti-CEACAM6 Antibody BAY1834942 | therapeutic_agents	C1909	therapeutic_agents
D	C177537	GDC Value Terminology	C162479	BTK inhibitor TG-1701	An orally available irreversible inhibitor of Bruton's tyrosine kinase (BTK; Bruton agammaglobulinemia tyrosine kinase) with potential antineoplastic activity. Upon administration, BTK inhibitor TG-1701 covalently binds to and irreversibly inhibits BTK activity, thereby preventing the activation of the B-cell antigen receptor (BCR) signaling pathway and BTK-mediated activation of downstream survival pathways. This may inhibit the growth of malignant B-cells that overexpress BTK. BTK, a member of the Src-related BTK/Tec family of cytoplasmic tyrosine kinases, is overexpressed or mutated in B-cell malignancies; it plays an important role in the development, activation, signaling, proliferation and survival of B-lymphocytes.	BTK inhibitor TG-1701 | therapeutic_agents	C1909	therapeutic_agents
A	C177537	GDC Value Terminology	C166968	Biropepimut-S	A proprietary, peptide cancer vaccine comprised of multiple peptides derived from human melanoma antigen A3 (MAGE-A3; MAGEA3), with potential immunostimulating and antineoplastic activities. Upon administration, biropepimut-S may stimulate the immune system to mount specific responses from B-cells, and CD4-positive and CD8-positive cells against tumor cells expressing MAGE-A3, resulting in tumor cell lysis. MAGE-A3, a tumor-associated antigen (TAA), is overexpressed by a variety of cancer cell types.	MAGE-A3 Multipeptide Vaccine GL-0817 | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C167335	Astrocytoma, IDH-Mutant, Grade 4	IDH-mutant astrocytoma characterized by the presence of necrosis and/or microvascular proliferation or homozygous deletion of CDKN2A and/or CDKN2B genes. The term glioblastoma no longer applies to central nervous system WHO grade 4 IDH-mutant astrocytomas. (WHO 2021)	9445/3 | morphology || Glioblastoma, IDH-mutant | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
A	C177537	GDC Value Terminology	C169931	Efgivanermin Alfa	A homogenous hexameric agonist fusion protein composed of the extracellular domain (ECD) of the T-cell costimulatory receptor human glucocorticoid-induced tumor necrosis factor receptor (tumor necrosis factor superfamily, member 18; TNFRSF18; GITR) ligand (GITRL) and an immunoglobulin (Ig) G1 Fc domain, with potential immunomodulating and antineoplastic activities. Upon administration, efgivanermin alfa binds to and activates GITR found on multiple types of T-cells, thereby inducing both the activation and proliferation of tumor antigen-specific T effector cells. This abrogates the suppression of T effector cells which is induced by inappropriately activated T regulatory cells (Tregs), suppresses Tregs and decreases Treg tumor infiltration, and activates the immune system to help eradicate tumor cells. GITR, a member of the TNF receptor superfamily, is expressed on the surface of multiple types of immune cells, including Tregs, effector T-cells, B-cells, dendritic cells (DCs) and natural killer (NK) cells.	GITR Agonist MEDI1873 | therapeutic_agents	C1909	therapeutic_agents
A	C177537	GDC Value Terminology	C170206	Necuparanib	A low molecular weight heparin derivative and heparan sulfate proteoglycan (HSPG) mimetic with no or minimal anticoagulant activity and potential antineoplastic activities. Upon administration, necuparanib mimics HSPGs by binding to and inhibiting various heparin-binding growth factors, chemokines, and cytokines such as VEGF, HGF, FGF2, SDF-1a, heparanase and P-selectin all of which are essential for tumor angiogenesis and metastasis to occur. This inhibits heparin binding growth factor-mediated signaling and disrupts tumor-stromal interactions eventually leading to an inhibition of angiogenesis and tumor cell progression. In addition, M402 may enhance the cytotoxic effect of other chemotherapeutic agents.	Heparan Sulfate Glycosaminoglycan Mimetic M402 | therapeutic_agents	C1909	therapeutic_agents
A	C177537	GDC Value Terminology	C170297	Pegcrisantaspase	A recombinant, pegylated form of Erwinia asparaginase (crisantaspase), derived from the bacterium Erwinia chrysanthemi and genetically engineered to be produced in Pseudomonas fluorescens, with potential antineoplastic activity. Recombinant Erwinia asparaginase hydrolyzes L-asparagine to L-aspartic acid and ammonia. This depletes cancer cells of asparagine, which blocks protein synthesis and tumor cell proliferation. Asparagine is critical to protein synthesis in cancer cells, which cannot synthesize this amino acid due to the absence of the enzyme asparagine synthase. Recombinant Erwinia asparaginase can be used as an alternative in patients who are hypersensitive to Escherichia (E.) coli-derived asparaginase products.	Pegylated Recombinant L-asparaginase Erwinia chrysanthemi | therapeutic_agents	C1909	therapeutic_agents
A	C177537	GDC Value Terminology	C171660	Felezonexor	An orally bioavailable inhibitor of the nuclear export protein exportin-1 (XPO1; chromosome region maintenance 1 protein homolog; CRM1), with potential antineoplastic and pro-apoptotic activities. Upon administration, felezonexor reversibly binds to the cargo binding site of XPO1, and prevents the XPO1-mediated nuclear export of cargo proteins, including tumor suppressor proteins (TSPs), such as p53, FOXO, p21, and p27, and leads to their selective accumulation in the nuclei of tumor cells. As a selective inhibitor of nuclear export (SINE), SL-801 restores the nuclear localization and function of TSPs, which leads to the induction of apoptosis in tumor cells. XPO1, the major export factor that transports proteins and RNA from the nucleus to the cytoplasm, is overexpressed in a variety of cancer cell types while minimally expressed in normal, healthy cells. The dysregulated export of TSPs into the cytoplasm prevents TSP-initiated apoptosis. XPO1 overexpression leads to uncontrolled tumor cell proliferation and is associated with poor prognosis.	XPO1 Inhibitor SL-801 | therapeutic_agents	C1909	therapeutic_agents
A	C177537	GDC Value Terminology	C171841	Tinurilimab	A humanized monoclonal antibody directed against the immune checkpoint regulator carcinoembryonic antigen-related cell adhesion molecule 6 (CEACAM6; CEACAM-6; CD66c), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration,tinurilimab targets, binds to and blocks the activity of CEACAM6 expressed on various tumor and immune cells, including T-cells. Blocking CEACAM6 signaling abrogates effector T-cell inhibition, activates antigen-specific T-lymphocytes, increases secretion of T-cell cytokines and effector molecules, and enhances cytotoxic T-cell-mediated tumor cell lysis, which results in a reduction in tumor cell proliferation. CEACAM6, an immune checkpoint receptor, is associated with tumor-mediated immune suppression. Elevated CEACAM6 expression is associated with advanced tumor stages and poor prognosis.	Anti-CEACAM6 Antibody BAY1834942 | therapeutic_agents	C1909	therapeutic_agents
A	C177537	GDC Value Terminology	C174762	Zoligratinib	An orally bioavailable inhibitor of the fibroblast growth factor receptor subtypes 1 (FGFR-1), 2 (FGFR-2) and 3 (FGFR-3), with potential antineoplastic activity. Zoligratinib binds to and inhibits FGFR-1, -2, and -3, which result in the inhibition of FGFR-mediated signal transduction pathways. This leads to the inhibition of both tumor cell proliferation and angiogenesis, and causes cell death in FGFR-overexpressing tumor cells. FGFR, a family of receptor tyrosine kinases upregulated in many tumor cell types, is essential for tumor cellular proliferation, differentiation and survival.	FGFR Inhibitor Debio 1347 | therapeutic_agents	C1909	therapeutic_agents
A	C177537	GDC Value Terminology	C175745	Autogene Cevumeran	An mRNA-based individualized, therapeutic cancer vaccine targeting an unspecified amount of tumor-associated antigens (TAAs) that are specifically expressed in the patient's cancer, with potential immunostimulatory and antineoplastic activities. Upon administration, autogene cevumeran is taken up and translated by antigen presenting cells (APCs) and the expressed protein is presented via major histocompatibility complex (MHC) molecules on the surface of the APCs. This leads to an induction of both cytotoxic T-lymphocyte (CTL)- and memory T-cell-dependent immune responses against cancer cells expressing the TAA(s).	Personalized Cancer Vaccine RO7198457 | therapeutic_agents	C1909	therapeutic_agents
A	C177537	GDC Value Terminology	C175775	Edralbrutinib	An orally available irreversible inhibitor of Bruton's tyrosine kinase (BTK; Bruton agammaglobulinemia tyrosine kinase) with potential antineoplastic activity. Upon administration, edralbrutinib covalently binds to and irreversibly inhibits BTK activity, thereby preventing the activation of the B-cell antigen receptor (BCR) signaling pathway and BTK-mediated activation of downstream survival pathways. This may inhibit the growth of malignant B-cells that overexpress BTK. BTK, a member of the Src-related BTK/Tec family of cytoplasmic tyrosine kinases, is overexpressed or mutated in B-cell malignancies; it plays an important role in the development, activation, signaling, proliferation and survival of B-lymphocytes.	BTK inhibitor TG-1701 | therapeutic_agents	C1909	therapeutic_agents
A	C177537	GDC Value Terminology	C175778	Emerfetamab	A bispecific T-cell engager (BiTE) antibody composed of two single-chain variable fragments (scFv), one directed against the tumor-associated antigen (TAA) CD33 fused to one that is directed against the CD3 antigen found on T-lymphocytes, with potential immunostimulating and antineoplastic activities. Upon administration, emerfetamab binds to both the CD3 antigen on cytotoxic T-lymphocytes (CTLs) and the CD33 antigen found on CD33-expressing tumor cells. This activates and redirects CTLs to CD33-expressing tumor cells, which results in the CTL-mediated cell death of CD33-expressing tumor cells. CD33, a myeloid differentiation antigen, is expressed on normal non-pluripotent hematopoietic stem cells and overexpressed on a variety of cancer cell types, including acute myeloid leukemia (AML). It plays a key role in tumor initiation, proliferation and progression.	Anti-CD33/CD3 BiTE Antibody AMG 673 | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C17998	Unknown	Not known, observed, recorded; or reported as unknown by the data contributor.	Unknown | adapter_content || Unknown | ajcc_clinical_m || Unknown | ajcc_clinical_n || Unknown | ajcc_clinical_stage || Unknown | ajcc_clinical_t || Unknown | ajcc_pathologic_m || Unknown | ajcc_pathologic_n || Unknown | ajcc_pathologic_stage || Unknown | ajcc_pathologic_t || Unknown | ajcc_staging_system_edition || Unknown | alcohol_history || Unknown | alcohol_intensity || Unknown | alcohol_type || Unknown | anaplasia_present || Unknown | anaplasia_present_type || Unknown | ann_arbor_b_symptoms || Unknown | ann_arbor_clinical_stage || Unknown | ann_arbor_extranodal_involvement || Unknown | ann_arbor_pathologic_stage || Unknown | antigen || Unknown | asbestos_exposure || Unknown | barretts_esophagus_goblet_cells_present || Unknown | basic_statistics || Unknown | biospecimen_anatomic_site || Unknown | biospecimen_laterality || Unknown | biospecimen_type || Unknown | bone_marrow_malignant_cells || Unknown | burkitt_lymphoma_clinical_variant || Unknown | cause_of_death || Unknown | cause_of_death_source || Unknown | cdc_hiv_risk_factors || Unknown | chemo_concurrent_to_radiation || Unknown | child_pugh_classification || Unknown | chipseq_antibody || Unknown | chipseq_target || Unknown | chromosome || Unknown | classification_of_tumor || Unknown | coal_dust_exposure || Unknown | cog_liver_stage || Unknown | cog_neuroblastoma_risk_group || Unknown | cog_renal_stage || Unknown | cog_rhabdomyosarcoma_risk_group || Unknown | columnar_mucosa_present || Unknown | comorbidity || Unknown | comorbidity_method_of_diagnosis || Unknown | composition || Unknown | diabetes_treatment_type || Unknown | diagnosis_pathologically_confirmed || Unknown | disease_response || Unknown | disease_type || Unknown | distance_normal_to_tumor || Unknown | dysplasia_degree || Unknown | dysplasia_type || Unknown | ecog_performance_status || Unknown | eln_risk_classification || Unknown | enneking_msts_grade || Unknown | enneking_msts_metastasis || Unknown | enneking_msts_stage || Unknown | enneking_msts_tumor_site || Unknown | environmental_tobacco_smoke_exposure || Unknown | esophageal_columnar_dysplasia_degree || Unknown | esophageal_columnar_metaplasia_present || Unknown | ethnicity || Unknown | exposure_duration || Unknown | figo_stage || Unknown | first_symptom_prior_to_diagnosis || Unknown | fragmentation_enzyme || Unknown | gastric_esophageal_junction_involvement || Unknown | gene_symbol || Unknown | goblet_cells_columnar_mucosa_present || Unknown | haart_treatment_indicator || Unknown | hepatitis_sustained_virological_response || Unknown | histone_family || Unknown | histone_variant || Unknown | hormonal_contraceptive_type || Unknown | hormonal_contraceptive_use || Unknown | hormone_replacement_therapy_type || Unknown | hpv_positive_type || Unknown | hysterectomy_margins_involved || Unknown | hysterectomy_type || Unknown | igcccg_stage || Unknown | imaging_result || Unknown | immunosuppressive_treatment_type || Unknown | initial_disease_status || Unknown | inpc_grade || Unknown | inpc_histologic_group || Unknown | inrg_stage || Unknown | inss_stage || Unknown | instrument_model || Unknown | irs_group || Unknown | irs_stage || Unknown | ishak_fibrosis_score || Unknown | iss_stage || Unknown | karnofsky_performance_status || Unknown | kmer_content || Unknown | laboratory_test || Unknown | largest_extrapelvic_peritoneal_focus || Unknown | laterality || Unknown | lost_to_followup || Unknown | lymph_node_involved_site || Unknown | lymph_node_involvement || Unknown | lymphatic_invasion_present || Unknown | margin_status || Unknown | medulloblastoma_molecular_classification || Unknown | menopause_status || Unknown | metaplasia_present || Unknown | metastasis_at_diagnosis || Unknown | metastasis_at_diagnosis_site || Unknown | method_of_diagnosis || Unknown | method_of_sample_procurement || Unknown | micropapillary_features || Unknown | mismatch_repair_mutation || Unknown | mitosis_karyorrhexis_index || Unknown | molecular_analysis_method || Unknown | morphology || Unknown | non_nodal_regional_disease || Unknown | non_nodal_tumor_deposits || Unknown | normal_tumor_genotype_snp_match || Unknown | ovarian_specimen_status || Unknown | ovarian_surface_involvement || Unknown | overrepresented_sequences || Unknown | per_base_n_content || Unknown | per_base_sequence_content || Unknown | per_base_sequence_quality || Unknown | per_sequence_gc_content || Unknown | per_sequence_quality_score || Unknown | per_tile_sequence_quality || Unknown | perineural_invasion_present || Unknown | peripancreatic_lymph_nodes_positive || Unknown | peritoneal_fluid_cytological_status || Unknown | ploidy || Unknown | pregnancy_outcome || Unknown | pregnant_at_diagnosis || Unknown | premature_at_birth || Unknown | preservation_method || Unknown | primary_diagnosis || Unknown | primary_site || Unknown | prior_treatment || Unknown | procedures_performed || Unknown | progression_or_recurrence || Unknown | progression_or_recurrence_anatomic_site || Unknown | progression_or_recurrence_type || Unknown | race || Unknown | radon_exposure || Unknown | reflux_treatment_type || Unknown | relationship_primary_diagnosis || Unknown | relationship_type || Unknown | residual_disease || Unknown | respirable_crystalline_silica_exposure || Unknown | risk_factor || Unknown | risk_factor_treatment || Unknown | sample_type || Unknown | satellite_nodule_present || Unknown | second_gene_symbol || Unknown | secondhand_smoke_as_child || Unknown | sequence_duplication_levels || Unknown | sequence_length_distribution || Unknown | site_of_resection_or_biopsy || Unknown | smoking_frequency || Unknown | supratentorial_localization || Unknown | synchronous_malignancy || Unknown | target_capture_kit || Unknown | test_analyte_type || Unknown | test_result || Unknown | test_units || Unknown | therapeutic_agents || Unknown | time_between_waking_and_first_smoke || Unknown | tissue_or_organ_of_origin || Unknown | tissue_type || Unknown | tobacco_smoking_status || Unknown | transglottic_extension || Unknown | treatment_anatomic_site || Unknown | treatment_effect || Unknown | treatment_effect_indicator || Unknown | treatment_frequency || Unknown | treatment_intent_type || Unknown | treatment_outcome || Unknown | treatment_type || Unknown | tumor_confined_to_organ_of_origin || Unknown | tumor_descriptor || Unknown | tumor_focality || Unknown | tumor_grade || Unknown | tumor_regression_grade || Unknown | type_of_smoke_exposure || Unknown | variant_origin || Unknown | variant_type || Unknown | vascular_invasion_present || Unknown | vascular_invasion_type || Unknown | viral_hepatitis_serologies || Unknown | vital_status || Unknown | who_cns_grade || Unknown | who_nte_grade || Unknown | wilms_tumor_histologic_subtype || Unknown | zygosity || unknown | gender || unknown | prior_malignancy || unknown | progression_or_recurrence || unknown | relationship_gender || unknown | relative_with_cancer_history || unknown | treatment_or_therapy || unknown | vital_status	C102562 || C105721 || C106304 || C106317 || C106541 || C111073 || C112400 || C121007 || C123560 || C125738 || C126378 || C127768 || C127772 || C129439 || C13202 || C133427 || C133706 || C139007 || C140258 || C140259 || C140262 || C140266 || C141342 || C15256 || C15599 || C156421 || C156422 || C157110 || C157233 || C157410 || C157425 || C158874 || C159824 || C160720 || C160827 || C160996 || C16124 || C161320 || C16165 || C162221 || C164057 || C16457 || C16515 || C16564 || C166229 || C16687 || C17001 || C17049 || C17103 || C171253 || C17140 || C171435 || C173544 || C17357 || C173595 || C174459 || C175524 || C176287 || C176708 || C176985 || C177549 || C177550 || C177555 || C177556 || C177557 || C177558 || C177559 || C177561 || C177562 || C177564 || C177565 || C177566 || C177567 || C177568 || C177570 || C177571 || C177572 || C177573 || C177574 || C177575 || C177576 || C177578 || C177583 || C177585 || C177586 || C177587 || C177588 || C177589 || C177590 || C177591 || C177592 || C177593 || C177594 || C177595 || C177597 || C177598 || C177599 || C177600 || C177601 || C177603 || C177604 || C177605 || C177606 || C177607 || C177608 || C177609 || C177610 || C177611 || C177612 || C177613 || C177614 || C177616 || C177619 || C177620 || C177621 || C177622 || C177624 || C177625 || C177626 || C177627 || C177628 || C177630 || C177631 || C177632 || C177633 || C177634 || C177635 || C177636 || C177637 || C177638 || C177640 || C177641 || C178243 || C178276 || C178286 || C178287 || C178288 || C178289 || C185264 || C185265 || C185266 || C185267 || C185268 || C185269 || C185270 || C185271 || C185272 || C185273 || C185274 || C185275 || C18849 || C18919 || C1909 || C19232 || C19697 || C19770 || C19796 || C25185 || C25218 || C25294 || C25717 || C268 || C28013 || C28076 || C29878 || C2991 || C33027 || C35529 || C36037 || C36292 || C38032 || C4086 || C45824 || C45902 || C4809 || C49236 || C50995 || C53414 || C54398 || C55816 || C574 || C67415 || C70700 || C70713 || C70729 || C81229 || C81239 || C83280 || C83315 || C83393 || C85416 || C89081 || C90491 || C92808 || C93431 || C95149 || C99532	inpc_grade || ecog_performance_status || tumor_regression_grade || mitosis_karyorrhexis_index || menopause_status || igcccg_stage || premature_at_birth || child_pugh_classification || margin_status || figo_stage || alcohol_intensity || perineural_invasion_present || vascular_invasion_present || medulloblastoma_molecular_classification || chromosome || inrg_stage || mismatch_repair_mutation || iss_stage || enneking_msts_stage || enneking_msts_grade || enneking_msts_tumor_site || enneking_msts_metastasis || chemo_concurrent_to_radiation || hysterectomy_type || hormone_replacement_therapy_type || site_of_resection_or_biopsy || tissue_or_organ_of_origin || hpv_positive_type || first_symptom_prior_to_diagnosis || hormonal_contraceptive_use || tumor_focality || primary_site || lost_to_followup || lymphatic_invasion_present || satellite_nodule_present || transglottic_extension || prior_treatment || synchronous_malignancy || haart_treatment_indicator || metastasis_at_diagnosis || type_of_smoke_exposure || comorbidity || fragmentation_enzyme || ethnicity || tumor_descriptor || histone_family || ploidy || race || risk_factor || second_gene_symbol || environmental_tobacco_smoke_exposure || biospecimen_anatomic_site || variant_type || gender || gene_symbol || classification_of_tumor || peritoneal_fluid_cytological_status || cause_of_death_source || imaging_result || morphology || irs_group || irs_stage || ajcc_clinical_stage || ajcc_pathologic_stage || test_analyte_type || ann_arbor_clinical_stage || ann_arbor_pathologic_stage || ajcc_staging_system_edition || eln_risk_classification || comorbidity_method_of_diagnosis || inpc_histologic_group || who_cns_grade || who_nte_grade || wilms_tumor_histologic_subtype || progression_or_recurrence_anatomic_site || supratentorial_localization || distance_normal_to_tumor || radon_exposure || coal_dust_exposure || respirable_crystalline_silica_exposure || method_of_diagnosis || dysplasia_degree || target_capture_kit || ann_arbor_b_symptoms || ann_arbor_extranodal_involvement || bone_marrow_malignant_cells || burkitt_lymphoma_clinical_variant || columnar_mucosa_present || diagnosis_pathologically_confirmed || esophageal_columnar_metaplasia_present || gastric_esophageal_junction_involvement || barretts_esophagus_goblet_cells_present || goblet_cells_columnar_mucosa_present || hysterectomy_margins_involved || metaplasia_present || non_nodal_regional_disease || non_nodal_tumor_deposits || normal_tumor_genotype_snp_match || ovarian_surface_involvement || progression_or_recurrence || risk_factor_treatment || variant_origin || biospecimen_laterality || ajcc_clinical_m || ajcc_pathologic_m || ovarian_specimen_status || viral_hepatitis_serologies || instrument_model || ajcc_clinical_n || ajcc_pathologic_n || chipseq_antibody || chipseq_target || initial_disease_status || pregnant_at_diagnosis || histone_variant || primary_diagnosis || relationship_gender || cdc_hiv_risk_factors || metastasis_at_diagnosis_site || secondhand_smoke_as_child || smoking_frequency || time_between_waking_and_first_smoke || cog_liver_stage || cog_neuroblastoma_risk_group || cog_renal_stage || cog_rhabdomyosarcoma_risk_group || hepatitis_sustained_virological_response || ajcc_clinical_t || ajcc_pathologic_t || reflux_treatment_type || treatment_effect_indicator || progression_or_recurrence_type || esophageal_columnar_dysplasia_degree || relationship_primary_diagnosis || peripancreatic_lymph_nodes_positive || anaplasia_present || anaplasia_present_type || vascular_invasion_type || largest_extrapelvic_peritoneal_focus || adapter_content || basic_statistics || kmer_content || overrepresented_sequences || per_base_n_content || per_base_sequence_content || per_base_sequence_quality || per_sequence_gc_content || per_sequence_quality_score || per_tile_sequence_quality || sequence_duplication_levels || sequence_length_distribution || history_of_tumor || prior_malignancy || treatment_outcome || therapeutic_agents || preservation_method || tissue_type || molecular_analysis_method || tobacco_smoking_status || laterality || treatment_type || laboratory_test || vital_status || antigen || karnofsky_performance_status || tumor_grade || relative_with_cancer_history || disease_type || lymph_node_involved_site || lymph_node_involvement || tumor_confined_to_organ_of_origin || test_result || treatment_effect || dysplasia_type || zygosity || alcohol_type || residual_disease || treatment_or_therapy || disease_response || composition || treatment_intent_type || asbestos_exposure || immunosuppressive_treatment_type || test_units || method_of_sample_procurement || sample_type || treatment_anatomic_site || alcohol_history || cause_of_death || exposure_duration || biospecimen_type || relationship_type || inss_stage || treatment_frequency || pregnancy_outcome || hormonal_contraceptive_type || procedures_performed || ishak_fibrosis_score || diabetes_treatment_type
C	C177537	GDC Value Terminology	C1857	Panitumumab	A human IgG2kappa monoclonal antibody specific for the epidermal growth factor receptor (EGFR). Monoclonal antibody E7.6.3 binds to the EGFR, blocking the binding of epidermal growth factor and transforming growth factor alpha to EGFR-expressing cancer cells and ultimately inhibiting EGFR-dependent cell activation and proliferation. (NCI)	Panitumumab | therapeutic_agents	C1909	therapeutic_agents
D	C177537	GDC Value Terminology	C19151	Metastasis	The spread or migration of cancer cells from one part of the body (the organ in which it first appeared) to another. The secondary tumor contains cells that are like those in the original (primary) tumor.	Metastasis, NOS | metastasis_at_diagnosis	C162221	metastasis_at_diagnosis
D	C177537	GDC Value Terminology	C2539	EGFR Inhibitor BIBX 1382	A pyrimido-pyrimidine with antitumor activity. BIBX 1382 inhibits the intracellular tyrosine kinase domain of the Epidermal Growth Factor Receptor (EGFR) thus specifically reversing the aberrant enzymatic activity from overexpressed and constitutively activated EGFR, and subsequently inhibiting cell proliferation and inducing cell differentiation.	EGFR Inhibitor BIBX 1382 | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C3017	Ependymoma	A WHO grade 2, slow growing tumor of children and young adults, usually located intraventricularly. It is the most common ependymal neoplasm. It often causes clinical symptoms by blocking cerebrospinal fluid pathways. Key histological features include perivascular pseudorosettes and ependymal rosettes. (WHO)	9391/3 | morphology || CNS, ependymoma | tumor_code || Ependymoma, NOS | primary_diagnosis || Epithelial ependymoma | primary_diagnosis	C176985 || C177615 || C177621	morphology || tumor_code || primary_diagnosis
C	C177537	GDC Value Terminology	C3058	Glioblastoma	The most malignant astrocytic tumor (WHO grade 4).  It is composed of poorly differentiated neoplastic astrocytes and is characterized by the presence of cellular polymorphism, nuclear atypia, brisk mitotic activity, vascular thrombosis, microvascular proliferation, and necrosis. It typically affects adults and is preferentially located in the cerebral hemispheres. (Adapted from WHO)	01 | tumor_code_id || 02 | tumor_code_id || 03 | tumor_code_id || 04 | tumor_code_id || 10 | tumor_code_id || 20 | tumor_code_id || 62 | tumor_code_id || 9440/3 | morphology || CNS, glioblastoma (GBM) | tumor_code || Glioblastoma | primary_diagnosis || Glioblastoma | relationship_primary_diagnosis || Glioblastoma multiforme | primary_diagnosis || Spongioblastoma multiforme | primary_diagnosis	C176985 || C177584 || C177615 || C177621 || C178243	morphology || tumor_code_id || tumor_code || primary_diagnosis || relationship_primary_diagnosis
C	C177537	GDC Value Terminology	C3137	Inflammation	A finding of a localized protective response resulting from injury or destruction of tissues. Inflammation serves to destroy, dilute, or wall off both the injurious agent and the injured tissue. In the acute phase, inflammation is characterized by the signs of pain, heat, redness, swelling, and loss of function. Histologically, inflammation involves a complex series of events, including dilatation of arterioles, capillaries, and venules, with increased permeability and blood flow; exudation of fluids, including plasma proteins; and leukocyte migration into the site of inflammation.	Inflammation | additional_pathology_findings || Inflammation | risk_factor || Inflammation, Hyperkeratosis | risk_factor	C158809 || C17103	additional_pathology_findings || risk_factor
C	C177537	GDC Value Terminology	C3230	Meningioma	A generally slow growing tumor attached to the dura mater. It is composed of neoplastic meningothelial (arachnoidal) cells. It typically occurs in adults, often women and it has a wide range of histopathological appearances. Of the various subtypes, meningothelial, fibrous and transitional meningiomas are the most common. Most meningiomas are WHO grade 1 tumors, and some are WHO grade 2 or 3 tumors. Most subtypes share a common clinical behavior, although some subtypes are more likely to recur and follow a more aggressive clinical course. (Adapted from WHO)	9530/0 | morphology || Meningioma, NOS | primary_diagnosis || Meningiomas | disease_type	C176985 || C177621 || C2991	morphology || primary_diagnosis || disease_type
C	C177537	GDC Value Terminology	C3261	Metastatic Neoplasm	A tumor that has spread from its original (primary) site of growth to another site, close to or distant from the primary site.  Metastasis is characteristic of advanced malignancies, but in rare instances can be seen in neoplasms lacking malignant morphology.	8000/6 | morphology || Neoplasm, metastatic | primary_diagnosis || Tumor, metastatic | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
C	C177537	GDC Value Terminology	C38697	Sontuzumab	A humanized monoclonal antibody directed against the tumor associated antigen (TAA) mucin-1 (MUC1), with potential antineoplastic activity. Upon administration, sontuzumab targets and binds to MUC1 expressed on the surface of tumor cells, which may activate the immune system to induce an antibody-dependent cellular cytotoxicity (ADCC) against MUC1-expressing tumor cells. MUC1, a glycoprotein overexpressed on the surface of a variety of cancer cells, plays a key role in tumor cell survival and proliferation.	Monoclonal Antibody HuHMFG1 | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C4002	Extraosseous Plasmacytoma	A localized malignant neoplasm arising in an extraosseous site. It is composed of clonal (malignant) plasma cells forming a tumor mass. It most frequently involves the oropharynx, nasopharynx, sinuses, and larynx.	9734/3 | morphology || Extraosseous plasmacytoma | primary_diagnosis || Plasmacytoma, extramedullary | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
C	C177537	GDC Value Terminology	C4047	Pilocytic Astrocytoma	A WHO grade 1, relatively circumscribed, slowly growing, often cystic astrocytoma occurring in children and young adults.  Histologically it is characterized by a biphasic pattern with compacted bipolar cells associated with Rosenthal fibers and multipolar cells associated with microcysts and eosinophilic bodies/hyaline droplets. (WHO)	9421/1 | morphology || Pilocytic astrocytoma | primary_diagnosis || Piloid astrocytoma | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
C	C177537	GDC Value Terminology	C4049	Anaplastic Ependymoma	A WHO grade 3 malignant glioma of ependymal origin with accelerated growth and an unfavorable clinical outcome, particularly in children. It is characterized by high mitotic activity, often accompanied by microvascular proliferation and pseudo-palisading necrosis. (Adapted from WHO)	9392/3 | morphology || Ependymoma, anaplastic | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
C	C177537	GDC Value Terminology	C4050	Oligoastrocytoma	A WHO grade 2 tumor composed of a conspicuous mixture of two distinct neoplastic cell types morphologically resembling the tumor cells in oligodendroglioma and diffuse astrocytoma. (WHO)	9382/3 | morphology || Oligoastrocytoma | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
A	C177537	GDC Value Terminology	C40557	Metastatic Lesion	A tumor arising at a location distant to the primary lesion.	Metastasis, NOS | metastasis_at_diagnosis || Metastatic | tumor_descriptor || metastasis | classification_of_tumor	C162221 || C166229 || C174459	metastasis_at_diagnosis || tumor_descriptor || classification_of_tumor
C	C177537	GDC Value Terminology	C425	Dianhydrogalactitol	A bifunctional hexitol derivative with potential antineoplastic activity. Dianhydrogalactitol alkylates and cross-links DNA via an epoxide group during all phases of the cell cycle, resulting in disruption of DNA function and cell cycle arrest. (NCI04)	Bi-functional Alkylating Agent VAL-083 | therapeutic_agents || Dianhydrogalactitol | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C4323	Pleomorphic Xanthoastrocytoma	A WHO grade 2 astrocytic tumor with a relatively favorable prognosis.  It is characterized by pleomorphic and lipidized cells expressing GFAP often surrounded by a reticulin network and eosinophilic granular bodies. It presents in the superficial cerebral hemispheres and involves the meninges. It typically affects children and young adults.	9424/3 | morphology || Pleomorphic xanthoastrocytoma | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
C	C177537	GDC Value Terminology	C43234	Not Reported	Not provided or available.	Not Reported | adapter_content || Not Reported | adrenal_hormone || Not Reported | ajcc_clinical_m || Not Reported | ajcc_clinical_n || Not Reported | ajcc_clinical_stage || Not Reported | ajcc_clinical_t || Not Reported | ajcc_pathologic_m || Not Reported | ajcc_pathologic_n || Not Reported | ajcc_pathologic_stage || Not Reported | ajcc_pathologic_t || Not Reported | ajcc_staging_system_edition || Not Reported | alcohol_history || Not Reported | alcohol_intensity || Not Reported | alcohol_type || Not Reported | anaplasia_present || Not Reported | anaplasia_present_type || Not Reported | ann_arbor_b_symptoms || Not Reported | ann_arbor_clinical_stage || Not Reported | ann_arbor_extranodal_involvement || Not Reported | ann_arbor_pathologic_stage || Not Reported | antigen || Not Reported | asbestos_exposure || Not Reported | barretts_esophagus_goblet_cells_present || Not Reported | basic_statistics || Not Reported | biospecimen_anatomic_site || Not Reported | biospecimen_laterality || Not Reported | biospecimen_type || Not Reported | bone_marrow_malignant_cells || Not Reported | burkitt_lymphoma_clinical_variant || Not Reported | cause_of_death || Not Reported | cause_of_death_source || Not Reported | cdc_hiv_risk_factors || Not Reported | chemo_concurrent_to_radiation || Not Reported | child_pugh_classification || Not Reported | chromosome || Not Reported | cog_liver_stage || Not Reported | cog_neuroblastoma_risk_group || Not Reported | cog_renal_stage || Not Reported | cog_rhabdomyosarcoma_risk_group || Not Reported | columnar_mucosa_present || Not Reported | comorbidity || Not Reported | comorbidity_method_of_diagnosis || Not Reported | composition || Not Reported | consistent_pathology_review || Not Reported | diabetes_treatment_type || Not Reported | diagnosis_pathologically_confirmed || Not Reported | disease_response || Not Reported | disease_type || Not Reported | distance_normal_to_tumor || Not Reported | dysplasia_degree || Not Reported | dysplasia_type || Not Reported | ecog_performance_status || Not Reported | eln_risk_classification || Not Reported | enneking_msts_grade || Not Reported | enneking_msts_metastasis || Not Reported | enneking_msts_stage || Not Reported | enneking_msts_tumor_site || Not Reported | esophageal_columnar_dysplasia_degree || Not Reported | esophageal_columnar_metaplasia_present || Not Reported | exposure_duration || Not Reported | eye_color || Not Reported | figo_stage || Not Reported | first_symptom_prior_to_diagnosis || Not Reported | gastric_esophageal_junction_involvement || Not Reported | gene_symbol || Not Reported | gleason_grade_group || Not Reported | goblet_cells_columnar_mucosa_present || Not Reported | haart_treatment_indicator || Not Reported | hepatitis_sustained_virological_response || Not Reported | histone_family || Not Reported | histone_variant || Not Reported | history_of_tumor || Not Reported | hormonal_contraceptive_type || Not Reported | hormonal_contraceptive_use || Not Reported | hormone_replacement_therapy_type || Not Reported | hpv_positive_type || Not Reported | hysterectomy_margins_involved || Not Reported | hysterectomy_type || Not Reported | igcccg_stage || Not Reported | imaging_result || Not Reported | immunosuppressive_treatment_type || Not Reported | initial_disease_status || Not Reported | inpc_grade || Not Reported | inpc_histologic_group || Not Reported | inrg_stage || Not Reported | inss_stage || Not Reported | instrument_model || Not Reported | irs_group || Not Reported | irs_stage || Not Reported | ishak_fibrosis_score || Not Reported | iss_stage || Not Reported | karnofsky_performance_status || Not Reported | kmer_content || Not Reported | laboratory_test || Not Reported | largest_extrapelvic_peritoneal_focus || Not Reported | laterality || Not Reported | lymph_node_involved_site || Not Reported | lymph_node_involvement || Not Reported | lymphatic_invasion_present || Not Reported | margin_status || Not Reported | medulloblastoma_molecular_classification || Not Reported | menopause_status || Not Reported | metaplasia_present || Not Reported | metastasis_at_diagnosis || Not Reported | metastasis_at_diagnosis_site || Not Reported | method_of_diagnosis || Not Reported | method_of_sample_procurement || Not Reported | micropapillary_features || Not Reported | mismatch_repair_mutation || Not Reported | mitosis_karyorrhexis_index || Not Reported | molecular_analysis_method || Not Reported | morphology || Not Reported | necrosis_present || Not Reported | non_nodal_regional_disease || Not Reported | non_nodal_tumor_deposits || Not Reported | normal_tumor_genotype_snp_match || Not Reported | ovarian_specimen_status || Not Reported | ovarian_surface_involvement || Not Reported | overrepresented_sequences || Not Reported | parent_with_radiation_exposure || Not Reported | per_base_n_content || Not Reported | per_base_sequence_content || Not Reported | per_base_sequence_quality || Not Reported | per_sequence_gc_content || Not Reported | per_sequence_quality_score || Not Reported | per_tile_sequence_quality || Not Reported | perineural_invasion_present || Not Reported | peripancreatic_lymph_nodes_positive || Not Reported | peritoneal_fluid_cytological_status || Not Reported | ploidy || Not Reported | pregnancy_outcome || Not Reported | pregnant_at_diagnosis || Not Reported | premature_at_birth || Not Reported | preservation_method || Not Reported | primary_diagnosis || Not Reported | primary_site || Not Reported | prior_treatment || Not Reported | procedures_performed || Not Reported | progression_or_recurrence || Not Reported | progression_or_recurrence_anatomic_site || Not Reported | progression_or_recurrence_type || Not Reported | radon_exposure || Not Reported | reflux_treatment_type || Not Reported | relationship_primary_diagnosis || Not Reported | relationship_type || Not Reported | residual_disease || Not Reported | rhabdoid_present || Not Reported | risk_factor || Not Reported | risk_factor_treatment || Not Reported | route_of_administration || Not Reported | sample_type || Not Reported | sarcomatoid_present || Not Reported | satellite_nodule_present || Not Reported | second_gene_symbol || Not Reported | secondhand_smoke_as_child || Not Reported | sequence_duplication_levels || Not Reported | sequence_length_distribution || Not Reported | site_of_resection_or_biopsy || Not Reported | supratentorial_localization || Not Reported | synchronous_malignancy || Not Reported | test_analyte_type || Not Reported | test_result || Not Reported | test_units || Not Reported | therapeutic_agents || Not Reported | tissue_or_organ_of_origin || Not Reported | tissue_type || Not Reported | tobacco_smoking_status || Not Reported | transglottic_extension || Not Reported | treatment_anatomic_site || Not Reported | treatment_effect || Not Reported | treatment_effect_indicator || Not Reported | treatment_frequency || Not Reported | treatment_intent_type || Not Reported | treatment_outcome || Not Reported | treatment_type || Not Reported | tumor_confined_to_organ_of_origin || Not Reported | tumor_descriptor || Not Reported | tumor_focality || Not Reported | tumor_grade || Not Reported | tumor_regression_grade || Not Reported | undescended_testis_corrected || Not Reported | undescended_testis_corrected_laterality || Not Reported | undescended_testis_corrected_method || Not Reported | undescended_testis_history || Not Reported | undescended_testis_history_laterality || Not Reported | variant_type || Not Reported | vascular_invasion_present || Not Reported | vascular_invasion_type || Not Reported | viral_hepatitis_serologies || Not Reported | vital_status || Not Reported | who_cns_grade || Not Reported | who_nte_grade || Not Reported | wilms_tumor_histologic_subtype || Not Reported | zygosity || not reported | classification_of_tumor || not reported | ethnicity || not reported | gender || not reported | last_known_disease_status || not reported | prior_malignancy || not reported | progression_or_recurrence || not reported | race || not reported | relationship_gender || not reported | relative_with_cancer_history || not reported | treatment_or_therapy || not reported | vital_status	C102562 || C105721 || C106304 || C106317 || C106541 || C111073 || C112400 || C121007 || C123560 || C125738 || C126378 || C127768 || C127772 || C129439 || C13202 || C133427 || C133706 || C139007 || C140258 || C140259 || C140262 || C140266 || C141342 || C142346 || C15256 || C15599 || C156421 || C156422 || C157110 || C157233 || C157410 || C157425 || C157437 || C158874 || C160720 || C160827 || C160996 || C16124 || C161320 || C16165 || C162221 || C16457 || C16564 || C166229 || C16687 || C17001 || C17049 || C17103 || C171253 || C171435 || C173544 || C17357 || C173595 || C174459 || C175524 || C176287 || C176708 || C176985 || C177549 || C177550 || C177555 || C177556 || C177557 || C177558 || C177559 || C177561 || C177562 || C177564 || C177565 || C177566 || C177567 || C177568 || C177570 || C177571 || C177572 || C177573 || C177576 || C177578 || C177585 || C177586 || C177587 || C177588 || C177589 || C177590 || C177591 || C177592 || C177593 || C177594 || C177595 || C177596 || C177597 || C177598 || C177599 || C177600 || C177601 || C177602 || C177603 || C177605 || C177606 || C177607 || C177608 || C177609 || C177610 || C177611 || C177612 || C177616 || C177617 || C177619 || C177620 || C177621 || C177622 || C177624 || C177625 || C177626 || C177630 || C177631 || C177632 || C177633 || C177634 || C177635 || C177636 || C177637 || C177638 || C177640 || C177641 || C178243 || C178276 || C178286 || C178287 || C178288 || C178289 || C181720 || C181723 || C182060 || C182097 || C182099 || C182101 || C182102 || C182109 || C185264 || C185265 || C185266 || C185267 || C185268 || C185269 || C185270 || C185271 || C185272 || C185273 || C185274 || C185275 || C18849 || C18919 || C1909 || C19232 || C19697 || C19770 || C19796 || C25185 || C25218 || C25294 || C25717 || C268 || C28013 || C28076 || C29878 || C2991 || C33027 || C35529 || C36037 || C36292 || C38032 || C38114 || C39694 || C4086 || C45824 || C45902 || C4809 || C49236 || C50995 || C53414 || C54398 || C55816 || C574 || C67415 || C70700 || C70713 || C70729 || C81229 || C81239 || C83280 || C83315 || C83393 || C85416 || C89081 || C90491 || C92808 || C93431 || C95149 || C99532	inpc_grade || ecog_performance_status || tumor_regression_grade || mitosis_karyorrhexis_index || menopause_status || igcccg_stage || premature_at_birth || child_pugh_classification || margin_status || figo_stage || alcohol_intensity || perineural_invasion_present || vascular_invasion_present || medulloblastoma_molecular_classification || chromosome || inrg_stage || mismatch_repair_mutation || iss_stage || enneking_msts_stage || enneking_msts_grade || enneking_msts_tumor_site || enneking_msts_metastasis || chemo_concurrent_to_radiation || gleason_grade_group || hysterectomy_type || hormone_replacement_therapy_type || site_of_resection_or_biopsy || tissue_or_organ_of_origin || hpv_positive_type || first_symptom_prior_to_diagnosis || hormonal_contraceptive_use || tumor_focality || eye_color || primary_site || lymphatic_invasion_present || satellite_nodule_present || transglottic_extension || prior_treatment || synchronous_malignancy || haart_treatment_indicator || metastasis_at_diagnosis || comorbidity || ethnicity || tumor_descriptor || histone_family || ploidy || race || risk_factor || second_gene_symbol || biospecimen_anatomic_site || variant_type || gender || gene_symbol || classification_of_tumor || peritoneal_fluid_cytological_status || cause_of_death_source || imaging_result || morphology || irs_group || irs_stage || ajcc_clinical_stage || ajcc_pathologic_stage || test_analyte_type || ann_arbor_clinical_stage || ann_arbor_pathologic_stage || ajcc_staging_system_edition || eln_risk_classification || comorbidity_method_of_diagnosis || inpc_histologic_group || who_cns_grade || who_nte_grade || wilms_tumor_histologic_subtype || progression_or_recurrence_anatomic_site || supratentorial_localization || distance_normal_to_tumor || radon_exposure || method_of_diagnosis || dysplasia_degree || ann_arbor_b_symptoms || ann_arbor_extranodal_involvement || bone_marrow_malignant_cells || burkitt_lymphoma_clinical_variant || columnar_mucosa_present || diagnosis_pathologically_confirmed || esophageal_columnar_metaplasia_present || gastric_esophageal_junction_involvement || barretts_esophagus_goblet_cells_present || goblet_cells_columnar_mucosa_present || hysterectomy_margins_involved || metaplasia_present || necrosis_present || non_nodal_regional_disease || non_nodal_tumor_deposits || normal_tumor_genotype_snp_match || ovarian_surface_involvement || progression_or_recurrence || rhabdoid_present || risk_factor_treatment || biospecimen_laterality || ajcc_clinical_m || ajcc_pathologic_m || ovarian_specimen_status || viral_hepatitis_serologies || instrument_model || ajcc_clinical_n || ajcc_pathologic_n || initial_disease_status || last_known_disease_status || pregnant_at_diagnosis || histone_variant || primary_diagnosis || relationship_gender || cdc_hiv_risk_factors || metastasis_at_diagnosis_site || secondhand_smoke_as_child || cog_liver_stage || cog_neuroblastoma_risk_group || cog_renal_stage || cog_rhabdomyosarcoma_risk_group || hepatitis_sustained_virological_response || ajcc_clinical_t || ajcc_pathologic_t || reflux_treatment_type || treatment_effect_indicator || progression_or_recurrence_type || esophageal_columnar_dysplasia_degree || relationship_primary_diagnosis || peripancreatic_lymph_nodes_positive || anaplasia_present || anaplasia_present_type || vascular_invasion_type || largest_extrapelvic_peritoneal_focus || consistent_pathology_review || undescended_testis_corrected_laterality || parent_with_radiation_exposure || undescended_testis_corrected || undescended_testis_history || undescended_testis_corrected_method || undescended_testis_history_laterality || adrenal_hormone || adapter_content || basic_statistics || kmer_content || overrepresented_sequences || per_base_n_content || per_base_sequence_content || per_base_sequence_quality || per_sequence_gc_content || per_sequence_quality_score || per_tile_sequence_quality || sequence_duplication_levels || sequence_length_distribution || history_of_tumor || prior_malignancy || treatment_outcome || therapeutic_agents || preservation_method || tissue_type || molecular_analysis_method || tobacco_smoking_status || laterality || treatment_type || laboratory_test || vital_status || antigen || karnofsky_performance_status || tumor_grade || relative_with_cancer_history || disease_type || lymph_node_involved_site || lymph_node_involvement || tumor_confined_to_organ_of_origin || test_result || treatment_effect || route_of_administration || sarcomatoid_present || dysplasia_type || zygosity || alcohol_type || residual_disease || treatment_or_therapy || disease_response || composition || treatment_intent_type || asbestos_exposure || immunosuppressive_treatment_type || test_units || method_of_sample_procurement || sample_type || treatment_anatomic_site || alcohol_history || cause_of_death || exposure_duration || biospecimen_type || relationship_type || inss_stage || treatment_frequency || pregnancy_outcome || hormonal_contraceptive_type || procedures_performed || ishak_fibrosis_score || diabetes_treatment_type
C	C177537	GDC Value Terminology	C4325	Giant Cell Glioblastoma	A rare histological variant of glioblastoma with a predominance of bizarre, multinucleated giant cells, an occasionally abundant stromal reticulin network, and a high frequency of TP53 mutations. (WHO)	9441/3 | morphology || Giant cell glioblastoma | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
C	C177537	GDC Value Terminology	C4326	Anaplastic Oligodendroglioma	A WHO grade 3 oligodendroglioma with focal or diffuse malignant morphologic features (prominent nuclear pleomorphism, mitoses, and increased cellularity).	9451/3 | morphology || Oligodendroglioma, anaplastic | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
A	C177537	GDC Value Terminology	C44281	Failed	Having undergone failure; did not accomplish the intended purpose.	FAIL | adapter_content || FAIL | basic_statistics || FAIL | kmer_content || FAIL | overrepresented_sequences || FAIL | per_base_n_content || FAIL | per_base_sequence_content || FAIL | per_base_sequence_quality || FAIL | per_sequence_gc_content || FAIL | per_sequence_quality_score || FAIL | per_tile_sequence_quality || FAIL | sequence_duplication_levels || FAIL | sequence_length_distribution	C185264 || C185265 || C185266 || C185267 || C185268 || C185269 || C185270 || C185271 || C185272 || C185273 || C185274 || C185275	adapter_content || basic_statistics || kmer_content || overrepresented_sequences || per_base_n_content || per_base_sequence_content || per_base_sequence_quality || per_sequence_gc_content || per_sequence_quality_score || per_tile_sequence_quality || sequence_duplication_levels || sequence_length_distribution
A	C177537	GDC Value Terminology	C47896	Warning	Cautionary advice about something.	WARN | adapter_content || WARN | basic_statistics || WARN | kmer_content || WARN | overrepresented_sequences || WARN | per_base_n_content || WARN | per_base_sequence_content || WARN | per_base_sequence_quality || WARN | per_sequence_gc_content || WARN | per_sequence_quality_score || WARN | per_tile_sequence_quality || WARN | sequence_duplication_levels || WARN | sequence_length_distribution	C185264 || C185265 || C185266 || C185267 || C185268 || C185269 || C185270 || C185271 || C185272 || C185273 || C185274 || C185275	adapter_content || basic_statistics || kmer_content || overrepresented_sequences || per_base_n_content || per_base_sequence_content || per_base_sequence_quality || per_sequence_gc_content || per_sequence_quality_score || per_tile_sequence_quality || sequence_duplication_levels || sequence_length_distribution
C	C177537	GDC Value Terminology	C4822	Malignant Glioma	A grade 3 or grade 4 glioma arising from the central nervous system. This category includes glioblastoma, anaplastic astrocytoma, anaplastic ependymoma, anaplastic oligodendroglioma, and anaplastic oligoastrocytoma.	9380/3 | morphology || Glioma, malignant | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
C	C177537	GDC Value Terminology	C62394	WHO Central Nervous System Grade 1	Describes central nervous system tumors that are generally low malignancy, non-infiltrative, and slow growing. Often they can be cured by surgery alone and there is a good chance of long term survival.	Grade I | who_cns_grade	C177566	who_cns_grade
C	C177537	GDC Value Terminology	C62395	WHO Central Nervous System Grade 2	Describes central nervous system tumors that are generally relatively slow growing and somewhat infiltrative. They may recur after treatment.	Grade II | who_cns_grade	C177566	who_cns_grade
C	C177537	GDC Value Terminology	C62396	WHO Central Nervous System Grade 3	Describes central nervous system tumors that are generally malignant and infiltrative. They tend to recur after treatment.	Grade III | who_cns_grade	C177566	who_cns_grade
C	C177537	GDC Value Terminology	C62397	WHO Central Nervous System Grade 4	Describes central nervous system tumors that are generally highly malignant, show rapid and aggressive growth, widely infiltrative, and prone to necrosis. They often recur rapidly after treatment.	Grade IV | who_cns_grade	C177566	who_cns_grade
C	C177537	GDC Value Terminology	C62409	Attenuated Listeria monocytogenes ANZ-100	A live-attenuated strain of the Gram-positive bacterium Listeria monocytogenes (Lm) with potential immunostimulatory and antineoplastic activities. Upon intravenous administration, attenuated Listeria monocytogenes ANZ-100 may accumulate in and infect liver cells where it may activate a potent innate immune response and an adaptive immune response involving the by recruitment and activation of T lymphocytes. This agent may potentiate the immune response to vaccines against various liver neoplasms.	Attenuated Listeria monocytogenes CRS-100 | therapeutic_agents	C1909	therapeutic_agents
D	C177537	GDC Value Terminology	C66988	Anti-IL-13 Humanized Monoclonal Antibody TNX-650	A humanized monoclonal antibody directed against interleukin-13 (IL-13) with potential antineoplastic activity. Anti-IL-13 humanized monoclonal antibody TNX-650 binds to and blocks the activity of IL-13, which may result in the inhibition of Hodgkin lymphoma cell proliferation. IL-13 cytokine, an important mediator in allergic inflammation, may be an autocrine growth factor for Hodgkin lymphoma cells.	Anti-IL-13 Humanized Monoclonal Antibody TNX-650 | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C6932	Solitary Plasmacytoma	A localized malignant neoplasm that arises in the bony skeleton or soft tissue. It is composed of clonal (malignant) plasma cells forming a tumor mass.	9731/3 | morphology || Solitary myeloma | primary_diagnosis || Solitary plasmacytoma | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
C	C177537	GDC Value Terminology	C6966	Pineocytoma	A WHO grade 1 slow growing tumor, more frequently affecting young adults. It is composed of small, uniform, mature cells resembling pineocytes with occasional large pineocytomatous rosettes. It may show a wide range of divergent phenotypes, including neuronal, glial, melanocytic, photoreceptor and mesenchymal differentiation. Pineocytoma generally has a relatively favorable prognosis. (Adapted from WHO)	9361/1 | morphology || Pineocytoma | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
C	C177537	GDC Value Terminology	C7173	Diffuse Astrocytoma	A low-grade (WHO grade 2) astrocytic neoplasm. It is characterized by diffuse infiltration of neighboring central nervous system structures. These lesions typically affect young adults and have a tendency for progression to anaplastic astrocytoma and glioblastoma. Based on the IDH genes mutation status, diffuse astrocytomas are classified as IDH-mutant, IDH-wildtype, and not otherwise specified.	9400/3 | morphology || Astrocytoma, low grade | primary_diagnosis || Cystic astrocytoma | primary_diagnosis || Diffuse astrocytoma | primary_diagnosis || Diffuse astrocytoma, low grade | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
A	C177537	GDC Value Terminology	C77600	Disufenton Sodium	A disulfonyl derivative of phenyl-tert-butyl nitrone (PBN), with potential anti-glioma activity. Although the exact mechanism(s) of action of OKN007 are still largely unknown, this agent appears to inhibit cancer cell proliferation and migration. This agent appears to inhibit the activity of sulfatase 2 (SULF2), a highly specific endoglucosamine-6-sulfatase that is overexpressed in the extracellular matrix of cancer cells and catalyzes the removal of sulfate from the 6-O-sulfate esters of heparin. In addition, OKN007 may induce changes in tumor metabolism and scavenge free radicals.	PBN Derivative OKN-007 | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C7812	Solitary Plasmacytoma of Bone	A localized malignant neoplasm that arises in the bone. It is composed of clonal (malignant) plasma cells forming a tumor mass. The most commonly affected bones are the vertebrae, ribs, skull, pelvis, and femur.	9731/3 | morphology || Plasmacytoma of bone | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
C	C177537	GDC Value Terminology	C78478	Astuprotimut-R	A cancer vaccine consisting of a recombinant form of human melanoma antigen A3 (MAGE-A3) combined with a proprietary adjuvant with potential immunostimulatory and antineoplastic activities. Upon administration, astuprotimut-R may stimulate a cytotoxic T lymphocyte (CTL) response against tumor cells expressing the MAGE-A3 antigen, resulting in tumor cell death. MAGE-A3, a tumor-associated antigen (TAA) originally discovered in melanoma cells, is expressed by various tumor types. The proprietary immunostimulating adjuvant in this agent is composed of a specific combination of immunostimulating compounds selected to increase the anti-tumor immune response to MAGE-A3.	Astuprotimut-R | therapeutic_agents || Immunotherapeutic GSK1572932A | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C78486	Anti-PLGF Monoclonal Antibody TB-403	A humanized immunoglobulin (Ig) G1 monoclonal antibody directed against the placenta growth factor (PGF), with potential anti-angiogenic and antineoplastic activities. Anti-PGF monoclonal antibody TB-403 binds to both PGF-1 and -2, thereby inhibiting the binding of PGF-1 and -2 to the vascular endothelial growth factor receptor-1 (VEGFR-1) and subsequent VEGFR-1 phosphorylation. This may result in the inhibition of tumor angiogenesis and tumor cell proliferation. PGF, a member of the VEGF sub-family and a key molecule in angiogenesis and vasculogenesis, is upregulated in many cancers.	Anti-PGF Monoclonal Antibody RO5323441 | therapeutic_agents || Anti-PLGF Monoclonal Antibody TB-403 | therapeutic_agents	C1909	therapeutic_agents
A	C177537	GDC Value Terminology	C80868	Falnidamol	A pyrimido-pyrimidine with antitumor activity. BIBX 1382 inhibits the intracellular tyrosine kinase domain of the Epidermal Growth Factor Receptor (EGFR) thus specifically reversing the aberrant enzymatic activity from overexpressed and constitutively activated EGFR, and subsequently inhibiting cell proliferation and inducing cell differentiation.	EGFR Inhibitor BIBX 1382 | therapeutic_agents	C1909	therapeutic_agents
A	C177537	GDC Value Terminology	C81275	Pass	One of two possible results of a pass/fail assessment; when the result satisfies a condition.	PASS | adapter_content || PASS | basic_statistics || PASS | kmer_content || PASS | overrepresented_sequences || PASS | per_base_n_content || PASS | per_base_sequence_content || PASS | per_base_sequence_quality || PASS | per_sequence_gc_content || PASS | per_sequence_quality_score || PASS | per_tile_sequence_quality || PASS | sequence_duplication_levels || PASS | sequence_length_distribution	C185264 || C185265 || C185266 || C185267 || C185268 || C185269 || C185270 || C185271 || C185272 || C185273 || C185274 || C185275	adapter_content || basic_statistics || kmer_content || overrepresented_sequences || per_base_n_content || per_base_sequence_content || per_base_sequence_quality || per_sequence_gc_content || per_sequence_quality_score || per_tile_sequence_quality || sequence_duplication_levels || sequence_length_distribution
A	C177537	GDC Value Terminology	C87767	Lebrikizumab	A humanized monoclonal antibody against interleukin 13 (IL-13) with immunosuppressive and anti-asthmatic activities. Lebrikizumab binds to IL-13 and inhibits IL-13-mediated pathways. IL-13, a cytokine mainly secreted by type 2 helper T cells, plays a key role in the induction of allergic inflammation.	Anti-IL-13 Humanized Monoclonal Antibody TNX-650 | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C88314	Tepotinib	An orally bioavailable inhibitor of MET tyrosine kinase with potential antineoplastic activity. Tepotinib selectively binds to MET tyrosine kinase and disrupts MET signal transduction pathways, which may induce apoptosis in tumor cells overexpressing this kinase. The receptor tyrosine kinase MET (also known as hepatocyte growth factor receptor or HGFR), is the product of the proto-oncogene c-Met and is overexpressed or mutated in many tumor cell types; this protein plays key roles in tumor cell proliferation, survival, invasion, and metastasis, and tumor angiogenesis.	Tepotinib | therapeutic_agents || c-Met Inhibitor MSC2156119J | therapeutic_agents	C1909	therapeutic_agents
D	C177537	GDC Value Terminology	C88325	Anti-IL-1 alpha Monoclonal Antibody MABp1	A human IgG1 monoclonal antibody directed against interleukin-1 alpha (IL1a) with potential A human IgG1 monoclonal antibody targeting the inflammatory cytokine interleukin-1 alpha (IL1a) with potential antineoplastic, anti-cachectic and anti-angiogenic activities. Anti-IL1a monoclonal antibody MABp1 targets and binds to IL1a and prevents IL1a activity. This prevents IL1a-mediated tumorigenesis and angiogenesis. In addition, MABp1 abrogates IL1a-mediated cachexia. IL1a, an inflammatory mediator expressed on monocytes, platelets and overexpressed by certain tumors, plays a key role in the promotion of tumor cell growth, metastasis and invasion. In addition, IL1a stimulates metabolic activity in the central nervous system.	Anti-IL-1 alpha Monoclonal Antibody MABp1 | therapeutic_agents	C1909	therapeutic_agents
D	C177537	GDC Value Terminology	C91386	Anti-PGF Monoclonal Antibody RO5323441	A humanized IgG1 monoclonal antibody directed against the placenta growth factor (PGF), with potential anti-angiogenic and antineoplastic activities. Anti-PGF monoclonal antibody RO5323441 binds to both PGF-1 and -2, thereby inhibiting the binding of PGF-1 and -2 to the vascular endothelial growth factor receptor-1 (VEGFR-1) and subsequent VEGFR-1 phosphorylation. This may result in the inhibition of tumor angiogenesis and tumor cell proliferation. PGF, a member of the VEGF sub-family and a key molecule in angiogenesis and vasculogenesis, is upregulated in many cancers.	Anti-PGF Monoclonal Antibody RO5323441 | therapeutic_agents	C1909	therapeutic_agents
D	C177537	GDC Value Terminology	C91714	Immunotherapeutic GSK1572932A	An immunotherapeutic containing a proprietary adjuvant system combined with a melanoma-associated antigen peptide MAGE-A3 epitope with potential immunomodulating and antineoplastic activities. Intramuscular administration with GSK1572932A may stimulate the immune system to exert both humoral and cellular immune responses against MAGE-A3-expressing tumor cells. MAGE-A3, a tumor associated antigen (TAA), is overexpressed in a variety of tumor cell types, including non-small cell lung cancer (NSCLC), melanoma, head and neck cancer, and bladder cancer.	Immunotherapeutic GSK1572932A | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C92552	Angiocentric Glioma	A WHO grade 1, slow-growing brain neoplasm of children and young adults, associated with epilepsy.  Morphologically it is characterized by an angiocentric pattern, monomorphic cellular infiltrate, and ependymal differentiation.	9431/1 | morphology || Angiocentric glioma | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
C	C177537	GDC Value Terminology	C92554	Papillary Glioneuronal Tumor	A WHO grade 1, indolent and relatively circumscribed brain tumor.  Morphologically it is characterized by the presence of astrocytes that line vascular and hyalinized pseudopapillae.  In between the pseudopapillae aggregates of neurocytes, large neurons, and ganglioid cells are present.	9509/1 | morphology || Papillary glioneuronal tumor | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
C	C177537	GDC Value Terminology	C92555	Extraventricular Neurocytoma	A WHO grade 2 neoplasm that arises from the brain parenchyma. Morphologically it is characterized by the presence of neoplastic uniform, round cells with neuronal differentiation. Unlike central neurocytoma, it does not involve the lateral ventricles. It usually affects young adults and has a favorable prognosis.	9506/1 | morphology || Extraventricular neurocytoma | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
C	C177537	GDC Value Terminology	C9349	Plasmacytoma	A malignant neoplasm characterized by the presence of a monoclonal population of plasma cells forming a tumor mass.	9731/3 | morphology || Plasmacytoma, NOS | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
C	C177537	GDC Value Terminology	C94524	Pituicytoma	An extremely rare, WHO grade 1, circumscribed and slow-growing tumor that arises from the neurohypophysis or infundibulum and described in adults.  It is characterized by the presence of elongated, spindle-shaped neoplastic glial cells that form storiform patterns or interlacing fascicular arrangements.  Signs and symptoms include visual disturbances, headache, amenorrhea, and decreased libido.	9432/1 | morphology || Pituicytoma | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
C	C177537	GDC Value Terminology	C9477	Anaplastic Astrocytoma	A diffusely infiltrating, WHO grade 3 astrocytoma with focal or dispersed anaplasia, and a marked proliferative potential. It may arise from a low-grade astrocytoma, but it can also be diagnosed at first biopsy, without indication of a less malignant precursor lesion. It has an intrinsic tendency for malignant progression to glioblastoma. (WHO)	9401/3 | morphology || Astrocytoma, anaplastic | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
C	C177537	GDC Value Terminology	C95708	Bermekimab	A human immunoglobulin (Ig) G1 monoclonal antibody directed against interleukin-1 alpha (IL-1a) and derived from human B-lymphocytes that were obtained from a natural human immune response against IL-1a, with potential antineoplastic, anti-inflammatory, anti-cachectic and anti-angiogenic activities. Upon administration, bermekimab targets, binds to and neutralizes IL-1a thereby preventing IL-1a activity. This prevents IL-1a-mediated inflammation, tumorigenesis and angiogenesis. In addition, bermekimab may abrogate IL-1a-mediated cachexia and stimulate metabolic activity in the central nervous system (CNS). IL-1a, an inflammatory mediator expressed on monocytes, platelets and overexpressed by certain tumors, plays a key role in the promotion of tumor cell growth, metastasis and invasion.	Anti-IL-1 alpha Monoclonal Antibody MABp1 | therapeutic_agents || Bermekimab | therapeutic_agents	C1909	therapeutic_agents
D	C177537	GDC Value Terminology	C99224	Bi-functional Alkylating Agent VAL-083	A bi-functional alkylating agent, with potential antineoplastic activity. Upon administration, VAL-083 crosses the blood brain barrier (BBB) and appears to be selective for tumor cells. This agent alkylates and crosslinks DNA which ultimately leads to a reduction in cancer cell proliferation. In addition, VAL-083 does not show cross-resistance to other conventional chemotherapeutic agents and has a long half-life in the brain.	Bi-functional Alkylating Agent VAL-083 | therapeutic_agents	C1909	therapeutic_agents